Summary This study aimed to assess the proportion of patients with advanced breast cancer who report benefit from first-line palliative chemotherapy using a simple global measure of wellbeing and to identify factors predicting benefit. A consecutive series of women with advanced breast cancer undergoing first-line palliative chemotherapy was evaluated. The main outcome measure was patient report of overall wellbeing assessed at post-treatment interview. Physical, psychological and functional status were assessed using the Rotterdam Symptom Checklist (RSCL) on three occasions (pretreatment, at the start of the third cycle and post treatment). It was planned that treatment would be discontinued after six cycles (i.e. 18-24 weeks). One hundred and sixty patients started treatment, of whom 155 were assessable for quality of life. After treatment, 41 (26%) patients reported they felt better, 29 (19%) felt the same and 34 (22%) felt worse than they did before treatment. The other 51 (33%) patients either died or stopped attending the hospital before the post-treatment interview and were assigned as treatment 'failures'. Patients who reported feeling better after treatment had improvements in psychological distress (P < 0.0001), pain (P = 0.01), lack of energy (P = 0.02) and tiredness (P = 0.02), as well as improvement in functional status (P = 0.07). Feeling better was also correlated with disease response (P = 0.03). Feeling worse after treatment or treatment 'failure' was predicted by the pretreatment presence of a dry mouth (P = 0.003) and high levels of psychological distress (P = 0.03). Pretreatment lack of energy (P = 0.01), dry mouth (P = 0.02), presence of liver metastases (P = 0.03) and breathlessness (P = 0.03) predicted treatment 'failures'. The results of this study suggest that first-line palliative chemotherapy for advanced breast cancer confers benefit on a substantial proportion of patients, with about one-quarter feeling better after treatment and nearly a half feeling better or the same some 4-6 months after the start of treatment. Factors identified in this study may assist clinicians in deciding which patients should not be offered treatment, because of high risk of feeling worse or treatment 'failure'. This work now needs to be validated on a further cohort of women receiving chemotherapy for advanced breast cancer.
Chemotherapy has been used widely in the management of patients with advanced breast cancer for over 20 years. When it was introduced, no randomized trials were undertaken to compare the benefits of chemotherapy with the best supportive care in terms of survival or quality of life. Disease response measured in terms of tumour shrinkage was, however, observed relatively frequently and this has been shown to be associated with relief of symptoms and improvement in quality of life (Baum et al, 1980) . In a few individual cases, chemotherapy probably prolongs survival by months or even years.
If chemotherapy was without toxicity, these benefits would almost certainly be considered worthwhile, even if they were only experienced by a small proportion of patients. The problem associated with making recommendations regarding the use of chemotherapy is that a considerable proportion of patients experience toxicity without gaining any benefits.
Chemotherapy is given for a range of reasons Maher et al, 1994) . These include relief of symptoms, delay or prevention of anticipated problems and possible prolongation of life. Treatment is sometimes given more in hope than expectation of benefit. Situations exist in which there is pressure on a clinician to use chemotherapy as a substitute for more appropriate support (Maher et al, 1994) . The overall aim of giving chemotherapy to patients with advanced breast cancer should be to optimize patients' quality of life.
A small number of recently conducted randomized controlled trials comparing different chemotherapy regimens in the treatment of advanced breast cancer have included quality of life as an outcome measure (Coates et al, 1987; Tannock et al, 1988; Richards et al, 1992; Fraser et al, 1993) . These have yielded important information about patient-reported benefit from treatment. The wider application of the results of these trials to the many clinical circumstances affecting patients with advanced breast cancer is, however, limited by the fact that the patients entered into such trials are not likely to be representative of all the patients the clinician sees. Many patients are not suitable for entry into a clinical trial, for example because they are too ill or refuse to give informed consent or are ineligible from a variety of restrictive selection criteria. A number of studies have suggested that patients entered into clinical trials have a better prognosis than those who are not (Maher, 1992) . A clearer appreciation of the impact on quality of life of palliative chemotherapy given to all patients with advanced breast cancer (whether in the context of a trial or empirically) should facilitate clinical decision making in this controversial area.
The main aim of this study was to define the proportion of patients who report benefit from first-line palliative chemotherapy in a consecutive series of women with advanced breast cancer. The second aim was to attempt to identify factors that predict which patients are likely to derive benefit in order to assist in the decision making process.
PATIENTS AND METHODS
All women with advanced breast cancer attending the Breast Unit at Guy's Hospital, London, UK, who were offered, and agreed to undergo, first-line palliative chemotherapy between May 1990 and June 1993 were eligible to participate in this study. In general, the policy adopted within the unit is to manage asymptomatic metastatic disease expectantly unless this is unacceptable to the patient or unless problems are considered likely to arise in the near future (e.g. some patients with lung metastases). Systemic therapy is given to patients with disease which cannot be controlled by local measures (e.g. radiotherapy, surgical excision, pleurodesis). Chemotherapy is normally reserved for the treatment of disease which can no longer be controlled by endocrine treatment, except in cases of rapidly progressive disease when a response to endocrine treatment is considered unlikely (e.g. lymphangitis carcinomatosa or liver metastases with deranged hepatic function).
Several chemotherapy regimens were used for first-line treatment during the study period, selection of which depended on the patients' overall condition, her previous exposure to adjuvant chemotherapy and on her agreement to participate in specific clinical trials. Two phase II chemotherapy trials [using iododoxorubicin (Twelves et al, 1 994a) and vinorelbine (Twelves et al, 1 994b)] as first-line palliative chemotherapy were conducted in this period. Patients with deranged liver function were normally treated with single-agent epirubicin (given either weekly or 3 weekly). Outside clinical trials, the preferred regimens were single-agent anthracyclines, cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and methotrexate, mitomycin and mitozantrone (MMM). It was planned that patients should receive six cycles of chemotherapy, at 3-to 4-weekly intervals, unless disease progression or toxicity prevented this. For those receiving weekly chemotherapy, the planned duration of treatment was 18 weeks.
Each patient was informed about the proposed treatment by a medical oncologist. This comprised an explanation of the nature and extent of the patient's disease and how this related to her symptoms, that there was a reasonable chance that chemotherapy could control the disease, but not cure it, and the possible sideeffects from treatment and the measures to be taken to counteract them. After the oncologist's explanation, the consent of the patient to participate in the quality of life assessments was sought by the study coordinator. Those who agreed to participate underwent assessments on three occasions: (i) pre-treatment -immediately before the first cycle of treatment;
(ii) intra-treatment -immediately before the third cycle of treatment; (iii) post treatment -at the first appointment after the last cycle of treatment;
A self-report questionnaire, the Rotterdam Symptom Check List (RSCL) (de Haes et al, 1990) , was administered at all three assessment points. A semistructured interview, developed specifically for the study, was conducted after the completion of treatment. (36) 5 (3) 51 (33) 74 (48) 23 (15) 7 (5) 67 (43) 15 (10) 15 (10) 8 (5) 35 (23) 11 (7) 4 (3) The RSCL incorporates items on a range of physical symptoms. Patients are asked to rate these items according to their experience during the previous week. Each item is scored between 0 (not at all) and 3 (very much). The RSCL also includes seven items concerned with psychological symptoms: feeling worried, irritable, nervous, depressed, anxious, tense and despondent about the future. These are scored on a similar four-point scale, and so possible scores on this seven-item subscale range from 0 to 21. A single item on functional status is rated 0 (up all day), 1 (up half the day), 2 (up for short periods) and 3 (confined to bed).
The post-treatment interview included two questions about the benefit of treatment. Patients were asked about their overall wellbeing -'How have you felt since just before starting treatmentbetter, the same or worse?' They were encouraged to expand their answer, which was recorded verbatim. Patients were also asked, 'How worthwhile do you feel treatment has been -very, moderately, a little or not at all?' Again, patients were invited to expand their response and their comments were recorded. An interview British Journal of Cancer (1998) 78(11) Fifty-one (33%) of the 155 patients were not available for posttreatment interview because of death during the treatment period (n = 39), early progression of disease before the planned midpoint assessment (n = 2) or because they discontinued treatment and stopped attending the unit (n = 10). One hundred and four patients (67%) underwent all three QoL assessments including the posttreatment interview. Forty-two of these patients had discontinued treatment early (but after the midpoint assessment) because of disease progression or toxicity. In 22 cases, the post-treatment assessment was conducted shortly after patients had commenced on second-line chemotherapy. However, no major differences were observed between those who were interviewed after starting second-line treatment and those who were being observed after discontinuing first-line treatment early. The median time between pretreatment assessment and the assessment before the third cycle was 6 (range 3-11) weeks. The median time between the first day of the last cycle and the post-treatment assessment was 4 (range 3-7) weeks.
As the main objective of palliative chemotherapy is to improve quality of life, the question about wellbeing was taken as the main outcome measure for the study. Patients were categorized into four groups as follows:
* those who felt better: n = 41 (26%); * those who felt the same as before treatment: n = 29 (19%); * those who felt worse: n = 34 (22%); * those who were unavailable for post-treatment assessment -'failures': n = 51 (33%).
For the purpose of this study, it was assumed that patients who were unavailable for a post-treatment assessment could not have benefited from treatment. The relationship between wellbeing as assessed by the patients and conventional disease response measurements is shown in Table 2 . Among the 104 patients who were fully assessed, a clear relationship was observed between disease response and wellbeing (x2 = 17.1, P = 0.03).
PHYSICAL SYMPTOMS
The six most commonly reported physical symptoms and their prevalence in the week before each assessment are shown for each of the four outcome groups in Table 3 . For each of these common symptoms, the lowest pretreatment prevalence of symptoms was among the group who reported feeling the same post treatment. Lack of energy and tiredness were the commonest symptoms before treatment, with over 60% of patients reporting moderate to severe levels of each of these symptoms. Patients who reported feeling better overall after treatment also reported significant improvements in their lack of energy (P = 0.02), tiredness (P = 0.02) and pain (P = 0.01) over the course of treatment (Table 3 , Figures 1 and 2 ). No such improvements were found for those who felt the same or worse after treatment. Patients reports of wellbeing after treatment were unrelated to changes in shortness of breath, lack of appetite and dry mouth (Table 3 and 
Worthwhileness
Half of the patients who were interviewed reported that they felt treatment had been moderately or very worthwhile, which represents one-third of all the patients who started treatment. Patients' view of the worthwhileness of treatment was associated with their report of wellbeing after treatment (%2 = 35. 1, P < 0.000 1) ( There were, however, 13 out of 104 (13%) patients who reported that the treatment was at least a little worthwhile, despite feeling worse than they did before treatment.
Example
Response to worthwhileness question:
'Had to try it -you have to don't you? I don't think it's done much for me though -perhaps I've had more time because of it, I don't know. If the doctors suggest it, it must be for a reason -you have it anyway.' Response to wellbeing question: 'Much worse. I can't get about any more, because I have so much pain. ' Wellbeing, worthwhileness and toxicity
The relationships between patient reports of wellbeing and worthwhileness at post-treatment interview and treatment toxicity have been examined. Patients' reports of nausea, vomiting and mouth problems on the RSCL at the midpoint of chemotherapy were used as markers of toxicity, as for each of these items the pretreatment incidence of moderate/severe problems was low among patients who subsequently completed a post-treatment interview and rose during the course of chemotherapy. The patients' reports of hair loss at the completion of treatment was used as a further marker of toxicity. No significant associations were found between these patient-rated markers of treatment toxicity and either wellbeing or worthwhileness after treatment. wellbeing. The factors included: sites of disease, number of sites of disease, pretreatment RSCL psychological, functional and physical (lacking energy, tiredness, pain, breathlessness, dry mouth and lacking appetite) scores. No factors were identified which predicted patients who subsequently felt better (n = 41), as opposed to those who subsequently felt the same or worse or who failed to reach the post-treatment interview (n = 114) according to logistic regression analysis. However, the presence of a dry mouth (P = 0.003) and high levels of psychological distress (P = 0.03) predicted feeling worse or failing (n = 75) as opposed to feeling better or the same (n = 80). Lacking energy (P = 0.01), the presence of a dry mouth (P = 0.02), of liver metastases (P = 0.03) and breathlessness (P = 0.03) predicted failing to reach the post-treatment interview (n = 51) as opposed to the other patient outcomes (n = 104).
Further logistic regression analyses were undertaken to examine whether any changes in quality of life scores between the pre-and intra-treatment assessments predicted post-treatment wellbeing. These analyses were based on 123 patients, 32 having failed to reach the second assessment. The factors examined included changes in RSCL scores for lacking energy, tiredness, pain, breathlessness, lacking appetite, having a dry mouth, functional status and psychological distress. Changes in tiredness (P = 0.002) and breathlessness (P = 0.06) predicted patients who subsequently felt better (n = 41), as opposed to those who felt the same, worse or who failed (n =82).
DISCUSSION
The combined complete and partial response rate in this study of 31 % of evaluable cases, is low compared with the 40-60% frequently reported for patients entered into phase III trials (Macauley and Smith, 1986) including those conducted in this unit (Steiner et al, 1983; Richards et al, 1992) . It is, nevertheless, in line with the response rate of 34% to first-line chemotherapy reported in an unselected series attending this unit (Gregory et al, 1993) . This supports the view that the extent of the benefit of first-line palliative chemotherapy, in terms of disease response, demonstrated in clinical trials is unlikely to apply to the totality of patients with advanced breast cancer receiving such treatment.
This study has demonstrated a clear relationship between disease response and patients' report of overall wellbeing after treatment, but the correlation is not exact. Whereas 61 % of patients who reported feeling better had a disease response, 17% of those feeling better had progressive disease and 24% of those feeling worse had a partial response. It would seem, therefore, that although the disease model of advanced breast cancer explains a good deal of patient wellbeing, it does not explain all of it. The finding of a relationship between disease response and wellbeing is in line with other studies in advanced breast cancer, which have shown that the quality of life of patients is improved by achieving tumour response (Baum et al, 1980; Coates et al, 1987) . Similar results have been reported in patients with other advanced forms of cancer, including small-cell lung cancer (Coates et al, 1983) , nonsmall-cell lung cancer (Kaasa et al, 1988) and colorectal cancer (Glimelius et al, 1989) .
The main assessment of outcome used in this study is a novel measure of overall patient wellbeing after treatment. Whereas it is recognized that for many clinical and research applications quality of life is optimally defined and assessed in terms of its component parts, a global assessment has utility in that it may capture information not covered by the more specific items and it might facilitate incorporating psychosocial variables into formal medical decision-making models, e.g. quality-adjusted life-year analysis.
It may also be useful in assessing the relative value attached to specific items or domains. The findings of this study suggest that feeling better after treatment with first-line palliative chemotherapy is associated with improvements in psychological distress, tiredness, lack of energy and pain.
Patients' perception of the worthwhileness of treatment was correlated with their report of wellbeing after chemotherapy, but not entirely so. As well as being related to improvement in quality of life, patients' views of worthwhileness may also reflect the hope that treatment brings. The provision of hope is one aspect of care that is rarely critically evaluated by doctors, being considered more of a philosophical than a medical issue (Slevin 1992) . However, in a study based on hypothetical treatment scenarios, patients with cancer who were about to undergo chemotherapy were asked to balance the price they would be prepared to pay in terms of side-effects for a particular degree of benefit. About half of patients reported they would accept intensive toxic chemotherapy for minimal benefit in terms of survival, prolongation of life or relief of symptoms (Slevin et al, 1990) . This is a hypothesis-generating study. There is preliminary evidence for the psychometric validity of the novel measure of overall patient wellbeing after treatment. The convergent validity of the measure, in this context, is demonstrated by the significant correlations between patients' report of feeling better and improvements in scores on a number of items/subscales of the RSCL. Similarly, the construct validity of the measure, in this context, is demonstrated by the significant correlation between feeling better and disease response. The approach to the assessment of benefit from palliative chemotherapy adopted in this study now needs further validation in a larger cohort of women with advanced breast cancer. If the study findings are confirmed, this would suggest that palliative chemotherapy confers benefit on a substantial proportion of patients with advanced breast cancer, with about a quarter feeling better after treatment and nearly a half feeling better or the same some 4-6 months after the start of treatment. The value to the patient of feeling the same after treatment is difficult to assess within the observational design of this study. The data indicate that those who reported feeling the same were on average less symptomatic at the start of chemotherapy. Clearly, it is more difficult for a patient to improve if they start out feeling relatively well. Nevertheless, for this group avoidance of deterioration may be beneficial. Theoretically, a randomized controlled trial might offer the study design within which to examine this issue, however the ethical and emotional objections to such a study would be likely to preclude its viability.
The study findings suggest that particular quality of life parameters can be identified which may assist clinicians in deciding which patients should not be offered treatment because of high risk of 'failure', and whether to stop treatment at midpoint because of a low chance of benefit. Other relevant predictive factors may be revealed from analysis of a larger cohort. If this approach is demonstrated to be robust in the assessment of palliative chemotherapy for advanced breast cancer, it may have wider application in the assessment of chemotherapy for other common cancer types and, thereby, help to inform not only individual clinical decision making but also resource allocation in a costly aspect of cancer care. 
